Topological analysis of p21(WAF1/CIP1) expression in esophageal squamous dysplasia

Yasuhiro Shirakawa, Yoshio Naomoto, Masashi Kimura, Ryuichi Kawashima, Tomoki Yamatsuji, Takahiko Tamaki, Madoka Hamada, Minoru Haisa, Noriaki Tanaka

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

In the normal stratified squamous epithelium of the esophagus, only the third to the fifth layers of cells express the cyclin-dependent kinase inhibitor p21(WAF1/CTP)1 (p21). Using immunohistochemical staining, we examined the topological distribution of cells expressing p21, p53, Ki67, and cytokeratin 10 (CK10), a differentiation marker of esophageal squamous cell carcinoma (SCC), in 25 superficial SCCs and 72 dysplastic lesions of the esophagus. Image analysis of p21, p53, and Ki67 expression was also performed in 48 dysplastic lesions. In superficial SCCs, although Ki67- and p53- expressing cells were mainly distributed in the deep layers of tumors despite tumor differentiation, the distribution of p21 correlated with tumor differentiation. In dysplastic lesions, p53- and Ki67-coexpressing cells tended to locate in the same layers and expand in the lower layers of epithelium with the progression of dysplasia, p21-expressing cells shifted to the upper layers of the epithelium with the progression of dysplasia. However, this change was heterogeneous; in some lesions, p21-expressing cells were confined to the superficial layers of atypical cells (confined type), whereas in others, p21-overexpressing cells were scattered among atypical cells (scattered type). CK10 expression was observed in 25% of dysplastic lesions, and the frequency of CK10 expression was significantly higher in the scattered than in the confined type. Our results suggest that esophageal squamous dysplasia represents the earliest pathological process in esophageal squamous carcinogenesis. Our results also suggest that differentiation of esophageal SCC is determined at the stage of dysplasia, and that p21 plays a critical role in the differentiation process.

Original languageEnglish
Pages (from-to)541-550
Number of pages10
JournalClinical Cancer Research
Volume6
Issue number2
Publication statusPublished - Feb 2000

Fingerprint

Keratins
Epithelium
Esophagus
Cyclin-Dependent Kinase Inhibitor p21
Cytidine Triphosphate
Neoplasms
Differentiation Antigens
Pathologic Processes
Carcinogenesis
Staining and Labeling
Esophageal Squamous Cell Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Shirakawa, Y., Naomoto, Y., Kimura, M., Kawashima, R., Yamatsuji, T., Tamaki, T., ... Tanaka, N. (2000). Topological analysis of p21(WAF1/CIP1) expression in esophageal squamous dysplasia. Clinical Cancer Research, 6(2), 541-550.

Topological analysis of p21(WAF1/CIP1) expression in esophageal squamous dysplasia. / Shirakawa, Yasuhiro; Naomoto, Yoshio; Kimura, Masashi; Kawashima, Ryuichi; Yamatsuji, Tomoki; Tamaki, Takahiko; Hamada, Madoka; Haisa, Minoru; Tanaka, Noriaki.

In: Clinical Cancer Research, Vol. 6, No. 2, 02.2000, p. 541-550.

Research output: Contribution to journalArticle

Shirakawa, Y, Naomoto, Y, Kimura, M, Kawashima, R, Yamatsuji, T, Tamaki, T, Hamada, M, Haisa, M & Tanaka, N 2000, 'Topological analysis of p21(WAF1/CIP1) expression in esophageal squamous dysplasia', Clinical Cancer Research, vol. 6, no. 2, pp. 541-550.
Shirakawa Y, Naomoto Y, Kimura M, Kawashima R, Yamatsuji T, Tamaki T et al. Topological analysis of p21(WAF1/CIP1) expression in esophageal squamous dysplasia. Clinical Cancer Research. 2000 Feb;6(2):541-550.
Shirakawa, Yasuhiro ; Naomoto, Yoshio ; Kimura, Masashi ; Kawashima, Ryuichi ; Yamatsuji, Tomoki ; Tamaki, Takahiko ; Hamada, Madoka ; Haisa, Minoru ; Tanaka, Noriaki. / Topological analysis of p21(WAF1/CIP1) expression in esophageal squamous dysplasia. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 2. pp. 541-550.
@article{0469812b5df74f32891def44118c2641,
title = "Topological analysis of p21(WAF1/CIP1) expression in esophageal squamous dysplasia",
abstract = "In the normal stratified squamous epithelium of the esophagus, only the third to the fifth layers of cells express the cyclin-dependent kinase inhibitor p21(WAF1/CTP)1 (p21). Using immunohistochemical staining, we examined the topological distribution of cells expressing p21, p53, Ki67, and cytokeratin 10 (CK10), a differentiation marker of esophageal squamous cell carcinoma (SCC), in 25 superficial SCCs and 72 dysplastic lesions of the esophagus. Image analysis of p21, p53, and Ki67 expression was also performed in 48 dysplastic lesions. In superficial SCCs, although Ki67- and p53- expressing cells were mainly distributed in the deep layers of tumors despite tumor differentiation, the distribution of p21 correlated with tumor differentiation. In dysplastic lesions, p53- and Ki67-coexpressing cells tended to locate in the same layers and expand in the lower layers of epithelium with the progression of dysplasia, p21-expressing cells shifted to the upper layers of the epithelium with the progression of dysplasia. However, this change was heterogeneous; in some lesions, p21-expressing cells were confined to the superficial layers of atypical cells (confined type), whereas in others, p21-overexpressing cells were scattered among atypical cells (scattered type). CK10 expression was observed in 25{\%} of dysplastic lesions, and the frequency of CK10 expression was significantly higher in the scattered than in the confined type. Our results suggest that esophageal squamous dysplasia represents the earliest pathological process in esophageal squamous carcinogenesis. Our results also suggest that differentiation of esophageal SCC is determined at the stage of dysplasia, and that p21 plays a critical role in the differentiation process.",
author = "Yasuhiro Shirakawa and Yoshio Naomoto and Masashi Kimura and Ryuichi Kawashima and Tomoki Yamatsuji and Takahiko Tamaki and Madoka Hamada and Minoru Haisa and Noriaki Tanaka",
year = "2000",
month = "2",
language = "English",
volume = "6",
pages = "541--550",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Topological analysis of p21(WAF1/CIP1) expression in esophageal squamous dysplasia

AU - Shirakawa, Yasuhiro

AU - Naomoto, Yoshio

AU - Kimura, Masashi

AU - Kawashima, Ryuichi

AU - Yamatsuji, Tomoki

AU - Tamaki, Takahiko

AU - Hamada, Madoka

AU - Haisa, Minoru

AU - Tanaka, Noriaki

PY - 2000/2

Y1 - 2000/2

N2 - In the normal stratified squamous epithelium of the esophagus, only the third to the fifth layers of cells express the cyclin-dependent kinase inhibitor p21(WAF1/CTP)1 (p21). Using immunohistochemical staining, we examined the topological distribution of cells expressing p21, p53, Ki67, and cytokeratin 10 (CK10), a differentiation marker of esophageal squamous cell carcinoma (SCC), in 25 superficial SCCs and 72 dysplastic lesions of the esophagus. Image analysis of p21, p53, and Ki67 expression was also performed in 48 dysplastic lesions. In superficial SCCs, although Ki67- and p53- expressing cells were mainly distributed in the deep layers of tumors despite tumor differentiation, the distribution of p21 correlated with tumor differentiation. In dysplastic lesions, p53- and Ki67-coexpressing cells tended to locate in the same layers and expand in the lower layers of epithelium with the progression of dysplasia, p21-expressing cells shifted to the upper layers of the epithelium with the progression of dysplasia. However, this change was heterogeneous; in some lesions, p21-expressing cells were confined to the superficial layers of atypical cells (confined type), whereas in others, p21-overexpressing cells were scattered among atypical cells (scattered type). CK10 expression was observed in 25% of dysplastic lesions, and the frequency of CK10 expression was significantly higher in the scattered than in the confined type. Our results suggest that esophageal squamous dysplasia represents the earliest pathological process in esophageal squamous carcinogenesis. Our results also suggest that differentiation of esophageal SCC is determined at the stage of dysplasia, and that p21 plays a critical role in the differentiation process.

AB - In the normal stratified squamous epithelium of the esophagus, only the third to the fifth layers of cells express the cyclin-dependent kinase inhibitor p21(WAF1/CTP)1 (p21). Using immunohistochemical staining, we examined the topological distribution of cells expressing p21, p53, Ki67, and cytokeratin 10 (CK10), a differentiation marker of esophageal squamous cell carcinoma (SCC), in 25 superficial SCCs and 72 dysplastic lesions of the esophagus. Image analysis of p21, p53, and Ki67 expression was also performed in 48 dysplastic lesions. In superficial SCCs, although Ki67- and p53- expressing cells were mainly distributed in the deep layers of tumors despite tumor differentiation, the distribution of p21 correlated with tumor differentiation. In dysplastic lesions, p53- and Ki67-coexpressing cells tended to locate in the same layers and expand in the lower layers of epithelium with the progression of dysplasia, p21-expressing cells shifted to the upper layers of the epithelium with the progression of dysplasia. However, this change was heterogeneous; in some lesions, p21-expressing cells were confined to the superficial layers of atypical cells (confined type), whereas in others, p21-overexpressing cells were scattered among atypical cells (scattered type). CK10 expression was observed in 25% of dysplastic lesions, and the frequency of CK10 expression was significantly higher in the scattered than in the confined type. Our results suggest that esophageal squamous dysplasia represents the earliest pathological process in esophageal squamous carcinogenesis. Our results also suggest that differentiation of esophageal SCC is determined at the stage of dysplasia, and that p21 plays a critical role in the differentiation process.

UR - http://www.scopus.com/inward/record.url?scp=0033621939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033621939&partnerID=8YFLogxK

M3 - Article

C2 - 10690537

AN - SCOPUS:0033621939

VL - 6

SP - 541

EP - 550

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -